Prasco to distribute Teva's generic of Adderall XR capsules

Press enter to search
Close search
Open Menu

Prasco to distribute Teva's generic of Adderall XR capsules

By Gina Acosta - 06/28/2016

CINCINNATI -- Prasco Laboratories has entered into agreements with Teva and Shire to acquire the rights to distribute the generic version of Adderall XR Extended Release Capsules. 

As a result of this acquisition, Prasco will market an AG version of Adderall XR Capsules, CII in the United States that is therapeutically equivalent and substitutable for prescriptions written for Adderall XR, a CNS stimulant that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

The Authorized Generic of Adderall XR is being divested by Teva as a precondition to its pending acquisition of Allergan's generics business. Upon closing of its transaction with Teva, Prasco will immediately take over the distribution of the product, providing a seamless transition for both customers and patients. 

"We are pleased to offer consumers an Authorized Generic of Adderall XR, thus allowing physicians, pharmacists, and consumers to experience product continuity between the brand and Prasco's therapeutically-equivalent AG version of Adderall XR," said Prasco CEO Chris Arington.